Immunome (IMNM) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zymeworks (ZYME) has outperformed Immunome (IMNM) over the past year, gaining 8.8% versus a loss of 15.3%. Over five years, ZYME leads with a +34.1% price change compared with -7.5% for IMNM. Immunome is the larger company by market cap ($1.85 billion vs $1.81 billion), about 1.0 times the size, while Zymeworks is growing revenue faster (+38.9% vs -23.2%).
Zymeworks converts more of its revenue into profit, with a net margin of -76.6% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | ZYME |
|---|---|---|
| Share price | $15.69 | $26.14 |
| Market cap | $1.85B | $1.81B |
| 1-day change | -5.54% | -2.68% |
| YTD return | -26.96% | -0.72% |
| 1-year return | -15.33% | +8.83% |
| 5-year return | -7.54% | +34.05% |
| P/E ratio (TTM) | — | 49.32 |
| Forward P/E | — | 54.95 |
| EPS (TTM) | $-2.63 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $105.97M |
| Revenue growth (YoY) | -23.23% | +38.87% |
| Net income (latest FY) | $-212.39M | $-81.13M |
| Operating margin | -3228.83% | -87.34% |
| Net margin | -3059.99% | -76.56% |
| 52-week high | $30.06 | $31.97 |
| 52-week low | $15.55 | $21.52 |
| Distance from 52-week high | -47.80% | -18.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.90% | +65.61% |
| Average volume | 1.36M | 1.09M |
| Shares outstanding | 118.07M | 68.70M |
| Employees | 267 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed IMNM by 24.2 percentage points over the past year.
- Zymeworks is more profitable, keeping -76.6 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Zymeworks grew revenue faster in its latest fiscal year (+38.87% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
IMNM vs ZYME FAQ
Which is bigger, Immunome or Zymeworks?
Immunome (IMNM) is larger, with a market capitalization of $1.85B compared with $1.81B for Zymeworks (ZYME).
Which stock has performed better over the past year, IMNM or ZYME?
ZYME returned +8.83% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.